New imaging agent shows promise for prostate cancer detection
NCT ID NCT06840535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal was to see if it is safe and to measure how much radiation the body receives. The agent helps doctors see where cancer has spread using a special scan.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Papa Giovanni XXIII
Bergamo, BG, 24127, Italy
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Milano, 20133, Italy
-
IRCCS Ospedale San Raffaele
Milan, Milano, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A surgical tweak may speed bladder control recovery after prostate removal
- Smarter prostate cancer screening: a blood test that may cut unnecessary biopsies
- Glow-in-the-dark dye may help surgeons spot hidden prostate cancer cells
- Blood DNA fragments and MRI join forces to spot hidden prostate cancer
- Can an AI agent match expert urologists? a major test begins
- Pumping iron to fight cancer's hidden immune toll